Key points are not available for this paper at this time.
Feline panleukopenia is a highly contagious and often fatal disease in cats caused by the feline panleukopenia virus (FPV), a member of the Parvoviridae family. Despite the widespread use of vaccination, FPV remains a significant threat to both domestic and wild felid populations worldwide, particularly in young or unvaccinated animals. Effective vaccination strategies are therefore essential for controlling the disease and reducing mortality. Current vaccines, including modified live and inactivated vaccines, have demonstrated substantial efficacy in inducing protective immunity; however, several challenges remain, such as maternal antibody interference, vaccine failure, and safety concerns in certain animal populations. Recent advances in vaccine technology have spurred the development of next-generation FPV vaccines, including recombinant vectors, DNA vaccines, virus-like particle (VLP) vaccines, and novel delivery platforms. Among these, probiotic-based vaccine vectors have garnered growing interest due to their favorable safety profiles, mucosal immunogenicity, and suitability for oral administration. These systems may provide innovative approaches for inducing both systemic and mucosal immune responses against FPV. This review summarizes the current understanding of the immunological mechanisms underlying protection against FPV infection and discusses the progress made in FPV vaccine development. Furthermore, it highlights the major challenges associated with current vaccination strategies and explores emerging vaccine platforms, including probiotic vector-based vaccines, as promising tools for future disease control. Improved vaccine design and optimized immunization strategies will be crucial for enhancing the prevention of feline panleukopenia in the future.
Zhu et al. (Tue,) studied this question.